Table 2.
Baseline characteristics of VACS 8 participants with HIV infection (n=3683), by OSA status
| HIV+, with OSA (n=143) |
HIV+, no OSA (n=3540) |
p-value | |
|---|---|---|---|
| DEMOGRAPHICS | |||
| Age in years, mean (SD) | 48.8 (8.9) | 49.3 (8.9) | 0.5 |
| Male gender, % | 98.6 | 97.5 | 0.6 |
| Race, % | 0.003 | ||
| Black | 57.3 | 70.5 | |
| White | 39.2 | 27.6 | |
| Other | 3.5 | 1.9 | |
| Body mass index (BMI), kg/m2, median (IQR) | 30.6 (26.0, 34.4) | 25.0 (22.5, 27.9) | <0.0001 |
| BMI <25 kg/m2, % | 14.8 | 50.7 | |
| BMI 25-35 kg/m2, % | 66.9 | 47.4 | |
| BMI >35 kg/m2, % | 18.3 | 1.8 | |
| CD4, median cells/ml (IQR) | 404 (257, 567) | 365 (207, 552) | 0.06 |
| CD4 <200 cells/ml, % | 16.2 | 23.5 | 0.05 |
| HIV RNA, median copies/ml (IQR) | 932(75, 20538) | 432 (75, 15300) | 0.4 |
| HIV RNA <400 copies/ml, % | 39.0 | 40.9 | 0.7 |
| Combination antiretroviral therapy use, % | 67.8 | 72.9 | 0.2 |
| Smoking status, % | 0.0006 | ||
| Current | 38.5 | 54.2 | |
| Former | 28.7 | 23.7 | |
| Never | 32.9 | 22.1 | |
| Hazardous alcohol use, % | 44.1 | 44.4 | 0.9 |
| COMORBIDITIES | |||
| Cardiovascular disease, % | 3.5 | 2.6 | 0.5 |
| Hypertension, % | 42.7 | 25.2 | <0.0001 |
| Diabetes, % | 43.4 | 24.6 | <0.0001 |
| Chronic obstructive pulmonary disease, % | 8.4 | 4.2 | 0.02 |
| Major depression, % | 15.4 | 11.1 | 0.1 |
| Hepatitis C, % | 21.0 | 27.1 | 0.1 |
| Hepatitis B, % | 4.2 | 4.5 | 0.9 |
|
OSA-RELATED TESTING, TREATMENT, AND
SYMPTOMS |
|||
| Polysomnogram, %* | 52.5 | 0.8 | <0.0001 |
| Home sleep test, %* | 4.2 | 0.1 | <0.0001 |
| CPAP CPT code, %* | 51.8 | 0.3 | <0.0001 |
| Tired/fatigue, % | 67.8 | 51.3 | 0.0001 |
| Concentration difficulty, % | 46.5 | 31.2 | 0.0009 |
| Self-reported sleep apnea during follow-up, %** |
58.7 | 6.2 | <0.0001 |
*
data include events at baseline or during follow-up
**
includes follow-up survey data from 112/143 (78%) OSA+ and 2376/3540 (67%) OSA negative HIV+ VACS 8 participants; p=0.005 between HIV+ OSA and HIV+ no OSA follow-up survey completion rate.